HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xellia Pharmaceuticals AS

www.xellia.com

Latest From Xellia Pharmaceuticals AS

US FDA Seeks Withdrawal Of Injectable Bacitracin Despite Extensive Off-Label Use

Injectable bacitracin, often used as a surgical irrigant, carries serious risks of nephrotoxicity and anaphylaxis; product is no longer prescribed for its lone approved indication in pediatric pneumonia. FDA’s decision aligns with advisory committee recommendations in 1984 and 2019.

 

Drug Safety Generic Drugs

Civica Rx Gets $55m Investment

Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.

Deals Strategy

Deal Watch: Roche Partners With Rheos To Develop Novel Immunometabolism Therapeutics

Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.

Deals M & A

Xellia and Kabi Broaden US Antibiotics Offering

Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.

Infectious Diseases Launches
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • Xellia Pharmaceuticals AS
  • Senior Management
  • Carl-Åke Carlsson, Pres. & CEO
    Kennet Lundberg, VP, CFO
    Gaël Bernard, VP, Sales & Mktg.
    Aleksandar Danilovski, VP, R&D
  • Contact Info
  • Xellia Pharmaceuticals AS
    Phone: 22 52 90 00
    Harbitzalléen 3
    P.O. Box 158 Oslo, 0212
    Norway
UsernamePublicRestriction

Register